Skip to content

Haemonetics

US · HAE #2165 by market cap Listed 1970
120.16 -0.21 -0.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 121.10 +0.61%
After-hours 120.16 0.00%
127.4265.88120.162026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on HAE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +35.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 7.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 53.2x Better than 9%
Forward P/E 27.5x Better than 21%
Price / Sales 4.0x Better than 29%
P/E vs own 5-yr range 78th pctl Better than 28%
Growth B

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 4.5% Better than 45%
Net income CAGR (3Y) -5.5% Better than 32%
Free cash flow CAGR (3Y) 47.2% Better than 83%
Profitability B

How much profit the business keeps from each dollar of sales and capital.

Gross margin 59.0% Better than 73%
Operating margin 18.1% Better than 72%
Net margin 7.3% Better than 51%
Return on equity 12.0% Better than 59%
Return on invested capital 5.9% Better than 49%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 10.4% Better than 90%
6-month return 83.5% Better than 99%
12-month return (ex latest month) 50.4% Better than 83%
Distance below 52-week high 9.0% Better than 86%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.0x Better than 72%
Debt to assets 51.1% Better than 14%
Interest coverage 5.5x Better than 58%
Free cash flow / net income 267.6% Better than 84%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 80.0% Better than 58%
Upside to average target 21.3% Better than 35%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.26%
1M +1.65%
3M +11.03%
6M +101.75%
YTD +49.92%
1Y +59.96%
3Y +44.89%
5Y +113.92%

Key statistics

Price & volume

Prev close
120.37
Open
120.37
Day range
119.68 - 122.34
Avg price
120.30
Volume
382.96K
Turnover
46.07M
Amplitude
2.21%
52-week range
51.00 - 132.00

Valuation

P/E
58.61
P/E (TTM)
53.17
P/B
6.09
EPS
2.05
Net profit
93.35M
Net assets
898.50M

Share structure

Market cap
5.47B
Float cap
5.40B
Shares out
45.54M
Float shares
44.93M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 85% of range
51.00 132.00

9.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+5.65M net over the window

Short interest

Shares short
3.60M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Haemonetics (HAE)?

Haemonetics last traded at 120.16. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Haemonetics's market cap?

About 5.47B.

What is the P/E ratio of Haemonetics?

The trailing twelve-month P/E is 53.17, above its own 5-year average of 42.15 — toward the top of its historical range (78.15% percentile). See the Valuation tab for the full history.

Does Haemonetics pay a dividend?

Haemonetics does not currently pay a regular dividend.

Is Haemonetics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 145.75, which implies 21.3% upside from the current price. This is not investment advice.

What is Haemonetics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Haemonetics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Haemonetics discussion 0 comments

Add a comment